Literature DB >> 8648221

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

J J Treanor1, R F Betts, G E Smith, E L Anderson, C S Hackett, B E Wilkinson, R B Belshe, D C Powers.   

Abstract

Healthy subjects <45 years old (young adults) or >65 (elderly adults) were randomized in double-blind fashion to receive intramuscularly subvirion trivalent influenza vaccine, placebo, or 15, 45, or 135 microgram of the hemagglutinin (HA) of the influenza A/Beijing/32/92 (H3N2) virus expressed in insect cells by a recombinant baculovirus (rHA0). All vaccines were well tolerated. Both young and elderly adults manifested serum hemagglutination-inhibition, virus neutralizing, and HA-specific IgG ELISA antibody responses to rHA0 vaccine. In young adults given 135 microgram of rHA0, the vaccine was significantly more immunogenic than subvirion influenza vaccine. Elderly adults also had increased antibody responses to 135 microgram of rHA0 compared with subvirion vaccine, but the difference was not statistically significant. These results demonstrate that high-dose rHA0 vaccines are well tolerated and effectively induce both functional and binding serum HA-specific antibody in young and elderly adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648221     DOI: 10.1093/infdis/173.6.1467

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Adaptation of an insect cell line of Spodoptera frugiperda to grow at 37 degrees C: characterization of an endodiploid clone.

Authors:  M Gerbal; P Fournier; P Barry; M Mariller; F Odier; G Devauchelle; M Duonor-Cerutti
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

Review 2.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

3.  Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Authors:  Bolyn Hubby; Todd Talarico; Maureen Maughan; Elizabeth A Reap; Peter Berglund; Kurt I Kamrud; Laura Copp; Whitney Lewis; Chad Cecil; Pamela Norberg; Jordan Wagner; Aubrey Watson; Sarah Negri; Bruce K Burnett; Andrew Graham; Jonathan F Smith; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-10-05       Impact factor: 3.641

4.  Influenza vaccination and the elderly: pandemic preparedness.

Authors:  Mary Jo Kasten; Gregory A Poland
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 6.  Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

7.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

8.  Seroepidemiology of astrovirus MLB1.

Authors:  Lori R Holtz; Irma K Bauer; Hongbing Jiang; Robert Belshe; Pamela Freiden; Stacey L Schultz-Cherry; David Wang
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

9.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

Review 10.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.